Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MaxCyte
Rockville, Maryland, United Statesinvestors.maxcyte.com ↗
- Ownership
- Public · MXCT
- Employees
- ~200
- Development stage
- Commercial
01
Overview
MaxCyte is a leading provider of non-viral cell engineering technologies. Its Flow Electroporation® and ExPERT™ platforms enable efficient transfection for cell and gene therapies. The technology has been used to support over 125 clinical programs—including the first FDA-approved CRISPR/Cas9 genome-edited cell therapy—and is integral to the manufacturing of next-generation therapeutics by major biopharma partners. While not developing its own drugs, MaxCyte’s platforms are critical enablers for industry-leading therapies such as CASGEVY® from Vertex/CRISPR Therapeutics.
- Modalities
- Cell therapyGene therapyProtein productionNon-viral cell engineering
- Industry
- Non-Drug Biotech
02
Partnerships
Vertex Pharmaceuticals / CRISPR Therapeutics (CASGEVY®, CRISPR/Cas9-edited therapies)Ori Biotech (cell therapy manufacturing automation)Over two dozen other biopharma companies via Strategic Platform License agreements (>29 SPLs signed)
03
Financials
- Market cap
- $136.6M
- Total revenue
- $7.3M
- Enterprise value
- $48.1M
Beyond the preview
Go deeper on MaxCyte.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MaxCyte.